Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (KR1020040029459) METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION

Office : Republic of Korea
Application Number: 1020047003107 Application Date: 02.03.2004
Publication Number: 1020040029459 Publication Date: 06.04.2004
Publication Kind : A
IPC:
A61K 31/44
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
CPC:
A61K 31/40
A61K 31/215
A61K 31/41
A61K 31/44
A61K 45/06
Y10S 514/824
Applicants: WARNER-LAMBERT COMPANY LLC
워너-램버트 캄파니 엘엘씨
Inventors: BOCAN THOMAS M. A.
보칸,토마스,엠.,에이.
Agents: 김영
위혜숙
Priority Data: 60/006,155 02.11.1995 US
Title: (EN) METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION
(KO) 지질 농도를 조절하는 제약 조성물 및 방법
Abstract:
(EN)

The present invention is a combination of an ACAT inhibitor, for example, sulfamic acid, [[2,4,6,-tris(1-methylethyl)phenyl]acetyl]-, 2,6- bis(1-methylethyl)phenyl ester, and an HMG-CoA-reductase inhibitor, for example, atorvastatin, effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoprotein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.

© KIPO & WIPO 2007


(KO) 본 발명은 지질 조절에 효과적인, 예를 들면, 술팜산, [[2,4,6-트리스(1-메틸에틸)-페닐]아세틸]-, 2,6-비스[(1-메틸에틸)페닐 에스테르와 같은 ACAT 억제제, 및 예를 들면, 아토르바스타틴과 같은 HMG-CoA 환원효소 억제제의 조합에 관한 것이다. 이러한 시약의 조합은 혈장 VLDL 및 LDL 콜레스테롤을 크게 감소시키며 어느 한 쪽 단독으로보다 HDL 콜레스테롤을 증가시켜서 아테롬 발생성 지단백질 특성을 적게 한다. 이 조합은 허혈성 증후군이 발병하거나 또는 발병의 위험이 있는 환자의 치료에서 내생적 혈관 내피 의존 활성을 회복하기 위해서 유용하다.
Also published as:
CZPV1998-1271IS4720NO19981961SK55798SG53241IL123902
EP0858336US6124309JPH11515025 CN1201389CN1679953CA2233558
EA199800420KR1019990067270NZ319906NZ512484AU1996072539IN2115/DEL/1996
GEP20001898BWO/1997/016184